The U.S. Food and Drug Administration has granted regulatory approval to Genentech's targeted oral therapy Itovebi (inavolisib), in combination with palbociclib (Ibrance) and fulvestrant, for the treatment of adult patients with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer. The indication applies to patients whose disease recurred on or after completing adjuvant endocrine therapy.
Activating mutations in the PIK3CA gene occur in approximately 40 percent of HR-positive metastatic breast cancers, driving rapid tumor proliferation and resistance to standard hormone therapies. Developed by Genentech, a member of the Roche Group, Itovebi is a next-generation, highly selective PI3K-alpha inhibitor engineered to degrade mutated p110-alpha protein while minimizing off-target toxicity.
Phase III INavo120 Trial Doubles Progression-Free Survival
The FDA's decision was anchored by results from the pivotal Phase III INavo120 clinical trial, which evaluated 325 patients across global oncology centers. In the first-line metastatic setting, the Itovebi-based triple regimen reduced the risk of disease progression or death by 57 percent compared with palbociclib and fulvestrant alone, extending median progression-free survival from 7.3 months to 15.0 months.
Objective response rates also improved markedly, reaching 58.4 percent in the Itovebi cohort versus 25.0 percent in the control arm. Because of the compelling clinical benefit, the agency evaluated the application under Priority Review and Breakthrough Therapy designation alongside the International Project Orbis oncology framework.
“With the approval of this Itovebi-based regimen, we are delivering a crucial targeted option that more than doubles progression-free survival for patients facing aggressive PIK3CA-mutated breast cancer.” — Levi Garraway, Chief Medical Officer and Head of Global Product Development at Genentech
Precision Biomarker Testing and Manageable Safety Profile
Alongside the therapeutic clearance, the FDA approved Foundation Medicine's FoundationOne Liquid CDx assay as a companion diagnostic to identify eligible patients via circulating tumor DNA in blood plasma. Oncologists emphasized that early genomic screening at the time of metastatic recurrence is essential to match patients with the triplet regimen immediately.
The most common adverse reactions reported in the trial included neutropenia, hyperglycemia, stomatitis, diarrhea, and fatigue, which were managed through standardized dose adjustments and monitoring protocols. Genentech confirmed that Itovebi will become available to specialty pharmacies across the United States within the coming weeks, while regulatory reviews continue before the European Medicines Agency.
Frequently Asked Questions
Which breast cancer patients are eligible for the newly approved Itovebi regimen?
Adults with endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative locally advanced or metastatic breast cancer detected by an FDA-approved test following adjuvant hormone therapy.
How effective was Itovebi in the Phase III INavo120 clinical trial?
The Itovebi combination more than doubled median progression-free survival to 15.0 months compared to 7.3 months with palbociclib and fulvestrant alone, cutting progression risk by 57 percent.
Comments (0)
Log in to join the discussion.